Clinical Trials

Merck Sharp & Dohme LLC has sponsored several clinical trials evaluating verubecestat (MK-8931) across Phase 1, Phase 2, and Phase 3 for neurodegenerative conditions, including Alzheimer's disease, amnestic mild cognitive impairment, and prodromal Alzheimer's disease. Early-phase studies successfully completed safety, pharmacokinetic, and pharmacodynamic evaluations in patient populations with renal or hepatic impairment as well as Alzheimer's disease. However, major late-stage Phase 2/3 and Phase 3 efficacy trials focusing on mild-to-moderate and prodromal Alzheimer's disease were ultimately terminated.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01953601 TERMINATED
Amnestic Mild Cognitive Impairment; Alzheimer's Disease; Prodromal Alzheimer's Disease
Merck Sharp & Dohme LLC
 2013-11-05 PHASE3
NCT01739348 TERMINATED
Alzheimer's Disease
Merck Sharp & Dohme LLC
 2012-11-30 PHASE2; PHASE3
NCT02910739 COMPLETED
Amnestic Mild Cognitive Impairment; Alzheimer's Disease; Prodromal Alzheimer's Disease
Merck Sharp & Dohme LLC
 2016-10-11 PHASE1
NCT02910739 Completed
Amnestic Mild Cognitive Impairment|Alzheimer''s Disease|Prodromal Alzheimer''s Disease
Merck Sharp & Dohme LLC
 2016-10-11 Phase 1
NCT01496170 COMPLETED
Alzheimer's Disease
Merck Sharp & Dohme LLC
 2011-12 PHASE1
NCT01537757 COMPLETED
Alzheimer's Disease
Merck Sharp & Dohme LLC
 2012-03 PHASE1
NCT01537757 Completed
Alzheimer''s Disease
Merck Sharp & Dohme LLC
 2012-03 Phase 1

(data from https://clinicaltrials.gov, updated on 2019-05-17)

Check the Verubecestat (MK-8931) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Verubecestat (MK-8931) potently and selectively binds to beta-site APP-cleaving enzyme 1 (BACE1), thereby blocking the rate-limiting endoproteolytic cleavage of amyloid precursor protein and suppressing downstream generation of neurotoxic amyloid-beta peptides. By halting amyloid-beta production and neurotoxic plaque accumulation, this mechanism directly addresses the primary pathological driver targeted in clinical trials for Alzheimer's disease, prodromal Alzheimer's disease, and amnestic mild cognitive impairment.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.